OnCo

Create your OnCo account

One account keeps your watchlist, saved views and cancer choice in sync across your devices, and lets OnCo alert you when a trial or treatment you follow changes. No password: we email you a sign-in link.

Account creation is being switched on. Until then, press Watch on any page and your list stays in this browser.

Living with cancer· Appointment prep

Appointment sheet: Metastatic hormone-sensitive prostate cancer

One page to bring and write on: your details, the questions for Metastatic hormone-sensitive prostate cancer plus your own, the words you may hear, what to bring, the treatments the standard of care names, and room for the answers and agreed next steps. What you type stays in this browser. Print it or save it as a PDF. New to all this? Start with the first 60 days. Orientation, not medical advice.

Tick the questions to print

All of this cancer's questions start ticked. Untick what does not apply; ticks are kept in this browser. .

Your own questions

Shared with the prep pack, so questions you add there appear here too.

Print or save as PDF

Use (or Ctrl+P, Cmd+P on a Mac). To keep a copy, choose Save as PDF as the destination in the print dialog. Only the sheet prints; the controls stay on screen. Your typed notes print where you typed them; empty fields print as ruled lines to write on.

Appointment sheet

Metastatic hormone-sensitive prostate cancer

Prepared with OnCo (onco.cc/prep/prostate-mhspc/). Orientation, not medical advice; your team knows your case.

My details

Name
Date of appointment
Hospital and clinician
Who is coming with me

What I know, what is unclear, changes to discuss

Saved in this browser
What I know so far
What is unclear to me
Changes since last time

My questions

22 on the sheet
Newly diagnosed
  1. 1.What is my exact diagnosis, stage, and grade, and which tests established them?
  2. 2.Which biomarkers have been tested on my tumour (for example Disease volume, De novo versus recurrent, PTEN loss by immunohistochemistry, PSMA PET positivity, Germline and tumour HRR genes), and what were the results?
  3. 3.Which subtype is my cancer, and does that change the recommended treatment?
  4. 4.Is germline (inherited) genetic testing recommended for me or my family?
All patients, backbone
  1. 5.For my situation (all patients, backbone), which of the standard options do you recommend and why?
  2. 6.Am I a candidate for Leuprolide (leuprorelin) and GnRH agonists, Degarelix, Relugolix, and what side effects should I expect?
Doublet therapy
  1. 7.For my situation (doublet therapy), which of the standard options do you recommend and why?
  2. 8.Am I a candidate for Abiraterone acetate, Enzalutamide, Apalutamide or related drugs, and what side effects should I expect?
  3. 9.How do the results of LATITUDE and STAMPEDE apply to someone like me?
Triplet therapy, high volume, fit for chemotherapy
  1. 10.For my situation (triplet therapy, high volume, fit for chemotherapy), which of the standard options do you recommend and why?
  2. 11.Am I a candidate for Docetaxel, Darolutamide, Abiraterone acetate, and what side effects should I expect?
  3. 12.How do the results of ARASENS and PEACE-1 apply to someone like me?
Low-volume disease
  1. 13.For my situation (low-volume disease), which of the standard options do you recommend and why?
  2. 14.How do the results of STAMPEDE apply to someone like me?
Biomarker-selected additions (2026)
  1. 15.For my situation (biomarker-selected additions (2026)), which of the standard options do you recommend and why?
  2. 16.Am I a candidate for Capivasertib, Lutetium-177 vipivotide tetraxetan, and what side effects should I expect?
  3. 17.How do the results of CAPItello-281 and PSMAddition apply to someone like me?
Any stage
  1. 18.Are there clinical trials I could join, for example of Capivasertib, Lutetium-177 vipivotide tetraxetan, PSMAddition, Relugolix?
  2. 19.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
  3. 20.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
  4. 21.I read that “Who needs triplet therapy and who is overtreated by it”. How does that affect my plan?
  5. 22.I read that “Whether intermittent or de-escalated therapy is safe after a deep PSA response”. How does that affect my plan?

The words I may hear

  • Androgen deprivation therapy (ADT): Switching off testosterone, the hormone that feeds prostate cancer, with injections (or tablets) that stop the testicles making it, or by removing them.
  • Oligometastatic disease: Cancer that has spread to only a few places, which may still be curable by treating each spot.

Tests and results to bring

Biomarker results to ask for: Disease volume (CHAARTED criteria), De novo versus recurrent, PTEN loss by immunohistochemistry, PSMA PET positivity, Germline and tumour HRR genes, PSA fall to below 0.2 at seven months (prognostic).

Scans and tests linked to this cancer: PSMA PET.

Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.

The treatments I may be offered

From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.

Answers and next steps

Saved in this browser
What I was told
Agreed next steps, dates and who to call